select trial semaglutide cardiovascular outcomes non-diabetic 2023 align more closely with attained dose than achieved weight loss The SELECT Trial - A

Even with a five-day half-life, the medication remains at a powerful therapeutic level for the full seven days between doses

Heading into 2026, several states have updated their rules, especially around weight management use

1.1 Brief history of GLP-1 discovery and development GLP-1 was discovered during research into the incretin effect, which occurs when oral glucose consumption leads to increased insulin production compared to intravenous glucose administration (Kreymann et al

10.1016/S0006-2952(99)00249-X

The latest on the scene: retatrutide , a so-called "triple-agonist" that targets GLP-1, GIP, and glucagon receptors

But staying with Transparent Labs for the other supplements isnt ideal if you want to maximize efficacy and minimize cost